Literature DB >> 7571368

Selective humoral immune response of Balb/C mice to Brucella abortus proteins expressed by vaccinia virus recombinants.

T E Toth1, J A Cobb, S M Boyle, R M Roop, G G Schurig.   

Abstract

Genes encoding Brucella abortus Cu/Zn superoxide dismutase (SOD) and a 54 kDa Escherichia coli HtrA homologue were cloned into shuttle plasmids pUV-1 and pSC11, and transfected into vaccinia virus to develop recombinants vUBSOD and vSB54. Control vaccinia virus recombinants vUV-1 and vSC11, carrying only the beta-gal reporter gene but no B. abortus DNA were also developed. Recombinants were analyzed in Western blotting using a polyclonal B. abortus immune serum. vUBSOD expressed a protein of apparent molecular weight of 28 kDa, composed of the 20 kDa B. abortus Cu/Zn-SOD and a protein approximately 8 kDa encoded by a portion of the vaccinia virus TK gene. vSB54 expressed a 54 kDa protein corresponding to the 54 kDa HtrA homologue. Recombinants vUSV-1 and vSC11 did not express B. abortus proteins. Groups of mice were inoculated intraperitoneally with 10(7) TCID50 of 1 of the 4 different recombinant vaccinia viruses and 5 weeks later their sera were analyzed for antibodies against vaccinia virus and B. abortus proteins. Each group of mice responded with antibodies to vaccinia virus. Sera of vSB54-inoculated mice recognized the 54 kDa HtrA homologue. vUBSOD did not induce a humoral immune response. These results represent the first report on the expression of B. abortus proteins by vaccinia virus recombinants and the first demonstrated immune response against a B. abortus protein expressed by such a recombinant.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7571368     DOI: 10.1016/0378-1135(95)00047-e

Source DB:  PubMed          Journal:  Vet Microbiol        ISSN: 0378-1135            Impact factor:   3.293


  6 in total

1.  Mutant Brucella abortus membrane fusogenic protein induces protection against challenge infection in mice.

Authors:  Job Alves de Souza Filho; Vicente de Paulo Martins; Priscila Carneiro Campos; Juliana Alves-Silva; Nathalia V Santos; Fernanda Souza de Oliveira; Gustavo B Menezes; Vasco Azevedo; Silvio Lorenzo Cravero; Sergio Costa Oliveira
Journal:  Infect Immun       Date:  2015-02-02       Impact factor: 3.441

2.  Immunization with a single dose of a microencapsulated Brucella melitensis mutant enhances protection against wild-type challenge.

Authors:  Angela M Arenas-Gamboa; Thomas A Ficht; Melissa M Kahl-McDonagh; Allison C Rice-Ficht
Journal:  Infect Immun       Date:  2008-03-24       Impact factor: 3.441

3.  Characterization of specific immune responses of mice inoculated with recombinant vaccinia virus expressing an 18-kilodalton outer membrane protein of Brucella abortus.

Authors:  R Vemulapalli; S Cravero; C L Calvert; T E Toth; N Sriranganathan; S M Boyle; O L Rossetti; G G Schurig
Journal:  Clin Diagn Lab Immunol       Date:  2000-01

4.  The Brucella abortus phosphoglycerate kinase mutant is highly attenuated and induces protection superior to that of vaccine strain 19 in immunocompromised and immunocompetent mice.

Authors:  Cyntia G M C Trant; Thais L S Lacerda; Natalia B Carvalho; Vasco Azevedo; Gracia M S Rosinha; Suzana P Salcedo; Jean-Pierre Gorvel; Sergio C Oliveira
Journal:  Infect Immun       Date:  2010-03-01       Impact factor: 3.441

5.  Protection of BALB/c mice against Brucella abortus 544 challenge by vaccination with bacterioferritin or P39 recombinant proteins with CpG oligodeoxynucleotides as adjuvant.

Authors:  A Al-Mariri; A Tibor; P Mertens; X De Bolle; P Michel; J Godefroid; K Walravens; J J Letesson
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 6.  Development and trial of vaccines against Brucella.

Authors:  Jonathan Lalsiamthara; John Hwa Lee
Journal:  J Vet Sci       Date:  2017-08-31       Impact factor: 1.672

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.